Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Adrian Haigh Sells 22,223 Shares

Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Adrian Haigh sold 22,223 shares of Fennec Pharmaceuticals stock in a transaction that occurred on Monday, April 22nd. The stock was sold at an average price of $9.32, for a total value of $207,118.36. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Adrian Haigh also recently made the following trade(s):

• On Friday, April 19th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $9.34, for a total value of $207,553.48.
• On Wednesday, April 17th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $9.91, for a total transaction of $220,220.02.
• On Monday, April 15th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $10.30, for a total transaction of $228,886.60.

Fennec Pharmaceuticals Price Performance

Shares of FENC stock opened at $9.38 on Tuesday. Fennec Pharmaceuticals Inc has a 1-year low of $6.30 and a 1-year high of $11.92. The firm has a market cap of $254.20 million, a PE ratio of -15.38 and a beta of 0.38. The company has a 50-day moving average of $10.05 and a two-hundred day moving average of $9.40.

Fennec Pharmaceuticals (NASDAQ:FENC) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12). The company had revenue of $9.74 million for the quarter, compared to analysts’ expectations of $9.47 million. Sell-side analysts anticipate that Fennec Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

FENC has been the subject of several analyst reports. Craig Hallum increased their price target on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the company a “buy” rating in a research note on Monday, March 18th. HC Wainwright upped their price objective on Fennec Pharmaceuticals from $17.00 to $18.00 and gave the company a “buy” rating in a report on Thursday, April 4th. Finally, Wedbush reissued an “outperform” rating and set a $16.00 target price on shares of Fennec Pharmaceuticals in a research note on Monday, March 18th.

Institutional Investors Weigh In On Fennec Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. AIGH Capital Management LLC lifted its stake in Fennec Pharmaceuticals by 6.9% during the 3rd quarter. AIGH Capital Management LLC now owns 373,526 shares of the company’s stock worth $2,805,000 after acquiring an additional 24,069 shares in the last quarter. Gendell Jeffrey L increased its stake in Fennec Pharmaceuticals by 0.9% during the third quarter. Gendell Jeffrey L now owns 285,992 shares of the company’s stock worth $2,148,000 after purchasing an additional 2,579 shares during the period. Worth Venture Partners LLC increased its stake in Fennec Pharmaceuticals by 52.7% during the fourth quarter. Worth Venture Partners LLC now owns 141,500 shares of the company’s stock worth $1,588,000 after purchasing an additional 48,864 shares during the period. Hartford Financial Management Inc. lifted its position in shares of Fennec Pharmaceuticals by 4.4% during the fourth quarter. Hartford Financial Management Inc. now owns 47,348 shares of the company’s stock worth $531,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Eudaimonia Advisors LLC boosted its stake in shares of Fennec Pharmaceuticals by 90.8% in the fourth quarter. Eudaimonia Advisors LLC now owns 32,686 shares of the company’s stock valued at $367,000 after purchasing an additional 15,556 shares during the period. 55.51% of the stock is owned by institutional investors and hedge funds.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.